X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Nuevolution Announces License Agreement with Merck

Yuvraj_pawp by Yuvraj_pawp
21st February 2014
in Europe, News

Copenhagen, Denmark, February 21, 2014 – Today announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.  

Under terms of the agreement, Merck will gain exclusive rights for the further development and commercialization of the compounds. This is the second agreement between Nuevolution and Merck. Nuevolution will receive an undisclosed upfront payment and milestone payments for certain preclinical, clinical and agreed upon commercial milestones.  In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.  Further financial details were not disclosed.

With this agreement, Nuevolution delivers on its new strategy to transform from a technology platform biotech company to a lead compound development company, providing novel products to improve future health treatments for patients.

 

Nuevolution applies its Chemetics® platform to identify small molecule drug candidates for therapeutically important targets. Chemetics® uses proprietary innovative DNA labelling to allow small molecule screening at an unprecedented scale for lead discovery. The technology allows efficient screening of billions of molecules against biological targets. Nuevolution has patented its Chemetics® technology and holds a strong validated patent portfolio within the technology field. In its existing collaborations and internal pipeline development, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.

 

“This agreement is the first pre-clinical compound out-licensing agreement for Nuevolution. It marks the immediate realization of our chosen strategy to both offer access to our technology as well as out-license leads identified by the use of the Chemetics® platform” said Alex Gouliaev, CEO of Nuevolution A/S and continued, “We are very pleased to see that the compounds will be developed further by Merck.”

 

Stig Løkke Pedersen, Chairman of Nuevolution A/S adds: “looking at our deal track record, Chemetics® has provided us with a commercially proven lead discovery engine. The out-licensing of compounds represents the best future source of sustainable growth for the company. It is very encouraging to see existing partnerships develop into long term relationships.”

Tags: Europe
Previous Post

Roche NimbleGen Introduces Novel NGS Target Enrichment Solution for Methylation Assessment

Next Post

Victoria Falls International Airport, Zimbabwe

Related Posts

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference
News

ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference

4th November 2019
Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment
Manufacturing

Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment

4th November 2019
Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards
Manufacturing

Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards

4th November 2019
Amgen declares positive results for 2 Phase 3 BLINCYTO studies
Clinical Trials

Amgen declares positive results for 2 Phase 3 BLINCYTO studies

10th October 2019
Next Post

Victoria Falls International Airport, Zimbabwe

Latest News

CPhI Worldwide pointing 2020 to be a strong year for pharma
Manufacturing

CPhI Worldwide pointing 2020 to be a strong year for pharma

3rd December 2019
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film
FDA Approvals

Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

26th November 2019
Med-Tech Innovation Expo and Medilink UK renew partnership
Drug Development

Med-Tech Innovation Expo and Medilink UK renew partnership

26th November 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In